To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on expanding the list of weight-related comorbidities on their tirzepatide guidance to include polycystic ovarian syndrome.
The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance that recommends tirzepatide to treat obesity, alongside a reduced calorie-diet and increased physical activity, in adults with a body mass index of 35...
Obesity: Drugs